First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma

MLA

Renee N Donahue, et al. “First-in-Human Phase Ib Trial of M9241 (NHS-IL12) plus Avelumab in Patients with Advanced Solid Tumors, Including Dose Expansion in Patients with Advanced Urothelial Carcinoma.” Journal for ImmunoTherapy of Cancer, vol. 11, no. 5, May 2023. EBSCOhost, https://doi.org/10.1136/jitc-2022-005813.

APA

Renee N Donahue, Jeffrey Schlom, James L Gulley, Mario Sznol, Andreas Schroeder, Julius Strauss, Luc Dirix, Michele Maio, Frank Beier, Alain Ravaud, Jean-Laurent Deville, Marco Maruzzo, XiaoZhe Wang, Yulia Vugmeyster, Sarah Chennoufi, Yo-Ting Tsai, Russell K Pachynski, Theodore S Gourdin, & Joerg Seebeck. (2023). First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma. Journal for ImmunoTherapy of Cancer, 11(5). https://doi.org/10.1136/jitc-2022-005813

Chicago

Renee N Donahue, Jeffrey Schlom, James L Gulley, Mario Sznol, Andreas Schroeder, Julius Strauss, Luc Dirix, et al. 2023. “First-in-Human Phase Ib Trial of M9241 (NHS-IL12) plus Avelumab in Patients with Advanced Solid Tumors, Including Dose Expansion in Patients with Advanced Urothelial Carcinoma.” Journal for ImmunoTherapy of Cancer 11 (5). doi:10.1136/jitc-2022-005813.